A monoclonal antibody to block tumor-associated immunosuppression by altering immune cell development will be developed in preparation for preclinical development and clinical trials.
ME Therapeutics Inc.
10 enregistrements totalisant 834,699.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $831,660 | 9 enregistrements |
| Emploi et Développement social Canada | $3,039 | 1 enregistrement |
Enregistrements
This project will involve testing the efficacy of a lead mRNA therapeutic and designing of novel mRNA sequence modifications to modulate mRNA expression in a tissue-specific manner.
The project will involve characterization of lead antibody product in in vivo cancer models to establish a robust efficacy profile.
The project involve efficacy evaluation of the novel pro-drug candidate formulations in various cancer models.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
This project will involve the testing of several potential cancer immunotherapy drug candidates discovered from an internal drug screening program.
N/A